NCT05161715View on ClinicalTrials.gov

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

May 9, 2023

Study Completion Date

June 1, 2023

Conditions
Early Alzheimer's Disease
Interventions
DRUG

Obicetrapib

10mg obicetrapib

Trial Locations (1)

Unknown

Brain Research Center Amsterdam, Amsterdam

Sponsors
All Listed Sponsors
lead

NewAmsterdam Pharma

INDUSTRY

NCT05161715 - Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease | Biotech Hunter | Biotech Hunter